Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03583866 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adiposity and Endothelin Receptor Function

Study acronym: END-RF
StatusActive, Not Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 6, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv6
  2. Primary completion date: Dec 2023 to Dec 2025
    • Study completion date: Jan 2024 to Jan 2026
    v5
  3. Primary completion date: Jun 2021 to Dec 2023v4 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 200 to confirmed 25
    • Study completion date: Jun 2021 to Jan 2024
    • Site details revised
  4. Primary completion date: Jun 2020 to Jun 2021v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Augusta University
25 trials monitored
See 1 trial at risk
Hypertension
1,925 trials monitored
See 99 trials at risk
Elevated levels of ET-1 have been implicated in cardiovascular disease and some forms of hypertension. Due to the strong, positive correlation between obesity and hypertension, the present study will explore the contribution of adiposity in ETB receptor function and aim to elucidate if ETB receptor dysfunction is a major contributor to hypertension in obesity.
Trial Details
NCT Number NCT03583866
Lead Sponsor Augusta University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions
(from sponsor)		 Hypertension
Related terms Hypertension
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov